In fiscal year 2017, the Foundation committed more than $10.4 million to support innovative research and training programs. The value of the Foundation’s programming is manifested in many ways: by the benefits to the grant recipients, who are supported in their careers at critical periods in their development as rheumatology leaders; by vital and needed advances in rheumatology research and training; and by the help provided to patients and their families through the innovative treatments and enriched supportive care that come as a result of funded research and training programs.
AWARDS BY THE NUMBERS

27 RESEARCH AWARDS
81 INSTITUTIONS
26 ANNUAL MEETING AWARDS
43 PRECEPTORSHIPS
12 FELLOWSHIP TRAINING AWARDS
6 HEALTH PROFESSIONAL ONLINE GRANTS
34 ANNUAL MEETING SCHOLARSHIPS
6 PEDIATRIC VISITING PROFESSORSHIPS
Awardees are using their funding to investigate the following diseases:

- Ankylosing Spondylitis
- Chikungunya Arthritis
- Cutaneous Lupus Erythematosus
- IgG4-Related Disease
- Juvenile Spondyloarthritis
- Myositis
- Osteoarthritis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Systemic Juvenile Idiopathic Arthritis
- Systemic Lupus Erythematosus

Annual Meeting Scholarships provide funding to attend the ACR/ARHP Annual Meeting to students and residents from these states underserved by rheumatology.

Project Outcomes*

Recipients shared the following research outcomes as a result of Foundation funding:

- 19 Defined New Pathways
- 2 New Cell Lines Developed
- 8 New Animal Models
- 3 Novel Gene Signatures
- 11 New Drug Targets
- 8 Better Diagnostic Tests
- 5 New Biomarkers
- 2 Drugs in Preclinical Testing
- 3 Novel Educational Products Developed
- 7 New Epidemiologic Findings
- 17 New Collaborative Networks
- 6 New Patient Databases

*(Based on 27 Final Reports)
The Rheumatology Research Foundation is a charitable 501(c)3 organization dedicated to advancing research and training to improve the health of people with rheumatic disease. The 2017 Annual Report is based on activities during Fiscal Year 2017 (July 1, 2016 – June 30, 2017)
**SUPPORTERS**

The generosity of our supporters is integral to our mission. Without the invaluable contributions of the rheumatology community, family members and friends, and the Corporate Roundtable, we could not spearhead the effort to end rheumatic disease. Thank you to the members of the FY 2017 Corporate Roundtable.

**LEADERSHIP**

**PINCALCE**

Genentech
*A Member of the Roche Group*

**PRINCIPAL**

AstraZeneca, Celgene, Lilly

**PARTNER**

Bristol-Myers Squibb, Janssen, Regeneron, Sanofi Genzyme

**EXECUTIVE**

GlaxoSmithKline

Thank you to the donors whose support was vital to Foundation programming.

- 56 Organizations
- 418 Patients, family members, and friends
- 4126 Rheumatologists and rheumatology health professionals

**FINANCIALS**

Rheumatology research and training is at the forefront of everything we do. Our high level of fiscal responsibility ranks us among the top 2% of charities in the nation and allows us to focus on what is the most important: the health of people living with rheumatic disease.

Charity Navigator is the nation’s largest charity evaluator, providing the Foundation with its highest rating of four stars for nine consecutive years.